Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 3, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving how doctors communicate with patients who have a type of cancer called large B-cell lymphoma, specifically a subtype known as diffuse large B-cell lymphoma (DLBCL). The study is testing a new training program called Hematolo-GIST, which aims to help oncologists have better conversations with their patients about their diagnosis and future care options.
To participate in this study, patients need to be at least 18 years old, be currently treated by a participating hematologic oncologist for DLBCL, and self-identify as Black and/or White. Additionally, they should have had a recent relapse or worsening of their lymphoma after initial treatments. Participants will be asked to complete certain study procedures, and they should be fluent in English to ensure they understand the discussions. This study is currently recruiting participants, and it presents an opportunity for patients to contribute to improving communication in cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hematologists
- • Currently a hemotologic oncologist providing care to patients with DLBCL
- • Patients
- • Per medical record, is being treated by a hematologic oncologist participating in this study
- • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
- • Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or autologous stem cell transplant (ASCT)
- • Self-identify as Black and/or White
- • Per medical record, 18 years of age or older
- * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
- • 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
- • 2. What is your preferred language for healthcare? (must respond English)
- Exclusion Criteria:
- • Hematologists
- • Per self-report, planning to leave the cancer center in the next 12 months
- • Patients
- • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
- • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
- • Per medical record or self-report, receiving hospice care at the time of enrollment
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Kelly McConnell, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported